Mercilon

Desogestrel and ethinylestradiol, the active ingredients in Mercilon, are a combined oral contraceptive presented as a 150 µg desogestrel / 20 µg ethinylestradiol tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Mercilon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Mercilon is marketed across the European Union and complies with EU pharmacovigilance regulations. This ensures consistent potency and safety for patients.

Mercilon, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy.

Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. Regulation of menstrual cycles: helps achieve more predictable and lighter menstrual bleeding. Management of acne: can improve acne symptoms by reducing androgenic activity. Reduction of dysmenorrhea: alleviates painful menstrual cramps. Treatment of endometriosis‑associated pain: may reduce pelvic pain symptoms.

Mercilon may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset, especially during the first cycles. - Headache: transient tension‑type headaches. - Breast tenderness: temporary swelling or discomfort. - Spotting or breakthrough bleeding: irregular bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism, potentially life‑threatening. - Stroke or myocardial infarction: rare cerebrovascular or cardiac events, more likely in smokers or high‑risk women. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention.

Before prescribing Mercilon, clinicians should evaluate several safety considerations. - Contraindications: known thrombosis, estrogen‑dependent tumor, pregnancy, or breastfeeding. - Smoking: avoid use in women over 35 who smoke due to increased cardiovascular risk. - Cardiovascular risk: assess history of hypertension, heart disease, or hyperlipidaemia. - Drug interactions: review concomitant medications that induce hepatic enzymes or affect coagulation. - Regular monitoring: check blood pressure and lipid profile periodically during therapy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Mercilon can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Rifampicin or other strong CYP3A4 inducers: can decrease hormone levels, increasing risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): may increase hormone concentrations, raising risk of side effects. - St. John’s wort: may lower hormone levels, potentially reducing contraceptive reliability. - HIV protease inhibitors (ritonavir): can affect hormone metabolism, requiring clinical monitoring.